Actinium Pharmaceuticals, Inc. ATNM
1.20
0.01
0.84%
as of 25 Sep
- Market cap
- $37.4M
- P/E
- 3.3×
Follow ATNM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(133.09%) | (166.96%) | (167.66%) | 45.86% | |
| (50.05%) | (52.67%) | (41.15%) | 21.92% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(72.45%) | (81.25%) | (64.87%) | 38.75% | |
Average Days of Receivables |
0.00 | — | — | 0.00 | |
Free Cash Flow per Share |
(0.80) | (0.79) | (0.74) | (0.74) | |
Free Cash Flow |
(25.04) | (24.68) | (22.98) | (23.25) | |
Capital Expenditures |
— | (0.10) | (0.11) | (0.58) | |
Piotroski F-Score |
2.00 | — | — | 5.00 | |
| Other line items | |||||
Cash ROIC |
(37.28%) | (44.02%) | (51.48%) | (33.94%) | |
Accounts Receivable Turnover |
0.00 | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
12,021.11% | 0.00% | 0.00% | 51.58% | |
Selling, General and Administrative Expense of Revenue |
8,772.22% | 0.00% | 0.00% | 21.09% | |
Share Based Compensation of Revenue |
5,768.33% | 0.00% | 0.00% | 0.71% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.72 | 0.73 | 0.97 | (2.00) | |
Depreciation/Fixed assets |
3.62 | 2.78 | 3.12 | 1.25 | |
Capex/Depreciation |
0.00 | (0.13) | (0.13) | (0.67) | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 1.12 | |
Operating CF per Share |
(0.80) | (0.79) | (0.73) | (0.72) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 | |
Net Profit Margin |
(19,221.67%) | 0.00% | 0.00% | 32.18% |
Columns are period end dates